SCHEMBL3449255

SCHEMBL3449255

Cc1ncc2n1C(=O)N(C1CCN(C(=O)CC(NC(=O)Nc3ccc(Cl)cc3)c3ccccc3)CC1)C2

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
F10 P00742 7/20 0.51
F2 P00734 3/20 0.51
UTS2R Q9UKP6 2/20 0.39
EPHX2 P34913 1/20 0.38
CCR1 P32246 1/20 0.38
NR3C1 P04150 1/20 0.38
ITGB3 P05106 1/20 0.36
ITGA2B P08514 1/20 0.36
CACNA2D1 P54289 4/20 0.36
CACNA1B Q00975 4/20 0.36
CACNB1 Q02641 4/20 0.36
CACNA1C Q13936 4/20 0.36
CALCRL Q16602 1/20 0.36
CACNA1G O43497 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3450991 0.88 F10 (0.54) F10F2EPHX2CCR1NR3C1
SCHEMBL3450667 0.87 F10 (0.51) F10F2CCR1NR3C1
SCHEMBL3449674 0.87 F10 (0.51) F10F2CCR1NR3C1
SCHEMBL3451847 0.87 F10 (0.51) F10F2CCR1NR3C1
SCHEMBL3449432 0.86 F10 (0.49) F10UTS2RCACNA2D1CACNA1BCACNB1
SCHEMBL3448801 0.83 F10 (0.51) F10F2CCR1NR3C1
SCHEMBL3449017 0.83 F10 (0.51) F10F2CCR1NR3C1
SCHEMBL3449287 0.83 F10 (0.51) F10F2CCR1NR3C1
SCHEMBL3449555 0.83 F10 (0.57) F10F2EPHX2NR3C1
SCHEMBL3450151 0.82 F10 (0.54) F10F2EPHX2CCR1NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820673-B2 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-7820673-B2 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-7820673-B2 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-20070093501-A1 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-26 US disclosed
US-20070093501-A1 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-26 US disclosed
US-20070093501-A1 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-26 US disclosed
EP-1695961-A1 UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2006-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093501-A1 Urea derivative, process for producing the same, and use F2, URB2, F12 F10 22/4885F2 1/4885UTS2R 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.